Literature DB >> 10216284

Effect of tranexamic acid and delta-aminovaleric acid on lipoprotein(a) metabolism in transgenic mice.

S Frank1, A Hrzenjak, K Kostner, W Sattler, G M Kostner.   

Abstract

The assembly of lipoprotein(a) (Lp(a)) is a two-step process which involves the interaction of kringle-4 (K-IV) domains in apolipoprotein(a) (apo(a)) with Lys groups in apoB-100. Lys analogues such as tranexamic acid (TXA) or delta-aminovaleric acid (delta-AVA) proved to prevent the Lp(a) assembly in vitro. In order to study the in vivo effect of Lys analogues, transgenic apo(a) or Lp(a) mice were treated with TXA or delta-AVA and plasma levels of free and low density lipoprotein bound apo(a) were measured. In parallel experiments, McA-RH 7777 cells, stably transfected with apo(a), were also treated with these substances and apo(a) secretion was followed. Treatment of transgenic mice with Lys analogues caused a doubling of plasma Lp(a) levels, while the ratio of free:apoB-100 bound apo(a) remained unchanged. In transgenic apo(a) mice a 1. 5-fold increase in plasma apo(a) levels was noticed. TXA significantly increased Lp(a) half-life from 6 h to 8 h. Incubation of McA-RH 7777 cells with Lys analogues resulted in an up to 1. 4-fold increase in apo(a) in the medium. The amount of intracellular low molecular weight apo(a) precursor remained unchanged. We hypothesize that Lys analogues increase plasma Lp(a) levels by increasing the dissociation of cell bound apo(a) in combination with reducing Lp(a) catabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216284     DOI: 10.1016/s1388-1981(99)00044-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism.

Authors:  Andelko Hrzenjak; Sasa Frank; Xingde Wo; Yonggang Zhou; Theo Van Berkel; Gert M Kostner
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

Review 2.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

3.  Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function.

Authors:  Jenny Sandmark; Anna Tigerström; Tomas Akerud; Magnus Althage; Thomas Antonsson; Stefan Blaho; Cristian Bodin; Jonas Boström; Yantao Chen; Anders Dahlén; Per-Olof Eriksson; Emma Evertsson; Tomas Fex; Ola Fjellström; David Gustafsson; Margareta Herslöf; Ryan Hicks; Emelie Jarkvist; Carina Johansson; Inge Kalies; Birgitta Karlsson Svalstedt; Fredrik Kartberg; Anne Legnehed; Sofia Martinsson; Andreas Moberg; Marianne Ridderström; Birgitta Rosengren; Alan Sabirsh; Anders Thelin; Johanna Vinblad; Annika U Wellner; Bingze Xu; Ann-Margret Östlund-Lindqvist; Wolfgang Knecht
Journal:  J Biol Chem       Date:  2020-03-04       Impact factor: 5.157

Review 4.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

5.  Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a).

Authors:  Yan-Ting Wang; Anne von Zychlinski; Sally P A McCormick
Journal:  J Lipid Res       Date:  2008-12-19       Impact factor: 5.922

6.  Lipoprotein(a): biology and clinical importance.

Authors:  Sally P A McCormick
Journal:  Clin Biochem Rev       Date:  2004-02

7.  Metabolic profiling of plasma from cardiac surgical patients concurrently administered with tranexamic acid: DI-SPME-LC-MS analysis.

Authors:  Barbara Bojko; Marcin Wąsowicz; Janusz Pawliszyn
Journal:  J Pharm Anal       Date:  2013-04-11

8.  Human apoB contributes to increased serum total apo(a) level in LPA transgenic mice.

Authors:  Päivi A Teivainen; Knut A Eliassen; Edward M Rubin; Srdjan Djurovic; Kåre Berg
Journal:  Lipids Health Dis       Date:  2004-05-11       Impact factor: 3.876

Review 9.  From organic and inorganic phosphates to valvular and vascular calcifications.

Authors:  Magnus Bäck; Jean-Baptiste Michel
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.